[go: up one dir, main page]

ES2113322A1 - Recombinant myxomatosis virus encoding non-myxomatosis antigen - for dual vaccination of rabbits and hares e.g. against myxomatosis and rabbit viral haemorrhagic disease - Google Patents

Recombinant myxomatosis virus encoding non-myxomatosis antigen - for dual vaccination of rabbits and hares e.g. against myxomatosis and rabbit viral haemorrhagic disease

Info

Publication number
ES2113322A1
ES2113322A1 ES09601551A ES9601551A ES2113322A1 ES 2113322 A1 ES2113322 A1 ES 2113322A1 ES 09601551 A ES09601551 A ES 09601551A ES 9601551 A ES9601551 A ES 9601551A ES 2113322 A1 ES2113322 A1 ES 2113322A1
Authority
ES
Spain
Prior art keywords
myxomatosis
recombinant
antigen
hares
rabbits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09601551A
Other languages
Spanish (es)
Other versions
ES2113322B1 (en
Inventor
Stephane Bertagnoli
Jacqueline Gelfi
Corine Boucrautbaralon
Frederque Petit
Alain Milon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Ecole Nationale Veterinaire de Toulouse ENVT
Original Assignee
Institut National de la Recherche Agronomique INRA
Ecole Nationale Veterinaire de Toulouse ENVT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA, Ecole Nationale Veterinaire de Toulouse ENVT filed Critical Institut National de la Recherche Agronomique INRA
Publication of ES2113322A1 publication Critical patent/ES2113322A1/en
Application granted granted Critical
Publication of ES2113322B1 publication Critical patent/ES2113322B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

VIRUS MIXOMATOSO RECOMBINANTE. VIRUS MIXOMATOSO RECOMBINANTE ATENUADO, QUE COMPRENDE POR LO MENOS UNA SECUENCIA NUCLEOTIDICA QUE CODIFICA PARA, Y QUE EXPRESA, UN POLIPEPTIDO ANTIGENO, BAJO LA DEPENDENCIA DE UN PROMOTOR, ESTANDO DICHA SECUENCIA Y DICHO PROMOTOR INSERTADOS EN UNO DE LOS GENES NO ESENCIAL PARA LA REPLICACION DE DICHO VIRUS. UTILIZACION DE DICHO VIRUS PARA LA FABRICACION DE UNA VACUNA DESTINADA A VACUNAR A LOS LEPORIDOS DE FORMA EFICAZ Y AL MISMO TIEMPO CONTRA LA MIXOMATOSIS Y CONTRA OTRA PATOLOGIA, ESPECIALMENTE LA RVHD. TAMBIEN SE REFIERE A UNA VACUNA PARA LEPORIDOS QUE COMPRENDE COMO VECTOR DICHO VIRUS MIXOMATOSO RECOMBINANTE ATENUADO.RECOMBINANT MYXOMA VIRUS. ATTENUATED RECOMBINANT MYXOMA VIRUS, COMPRISING AT LEAST ONE NUCLEOTIDE SEQUENCE ENCODING FOR, AND EXPRESSING, AN ANTIGEN POLYPEPTIDE, UNDER THE DEPENDENCE OF A PROMOTER, SAID SEQUENCE AND SAID PROMOTER BEING INSERTED IN ONE OF THE GENES NOT ESSENTIAL FOR REPLICATION OF SAID VIRUS. USE OF SAID VIRUS FOR THE MANUFACTURE OF A VACCINE INTENDED TO VACCINATE LEPORIDES EFFECTIVELY AND AT THE SAME TIME AGAINST MYXOMATOSIS AND AGAINST ANOTHER PATHOLOGY, ESPECIALLY RVHD. IT ALSO REFERS TO A VACCINE FOR LEPORIDES WHICH INCLUDES AS VECTOR SAID ATTENUATED RECOMBINANT MYXOMA VIRUS.

ES09601551A 1995-07-05 1996-07-05 RECOMBINANT MIXOMATOUS VIRUSES. Expired - Fee Related ES2113322B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9508128A FR2736358B1 (en) 1995-07-05 1995-07-05 RECOMBINANT MYXOMATOUS VIRUS

Publications (2)

Publication Number Publication Date
ES2113322A1 true ES2113322A1 (en) 1998-04-16
ES2113322B1 ES2113322B1 (en) 1998-12-01

Family

ID=9480712

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09601551A Expired - Fee Related ES2113322B1 (en) 1995-07-05 1996-07-05 RECOMBINANT MIXOMATOUS VIRUSES.

Country Status (4)

Country Link
DE (1) DE19627193B4 (en)
ES (1) ES2113322B1 (en)
FR (2) FR2736358B1 (en)
IT (1) IT1286307B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153284B1 (en) * 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De NEW RECOMBINANT VIRUS OF ATTENATED MIXOMA AND ITS USE IN THE PREPARATION OF MIXED VACCINES AGAINST MIXOMATOSIS AND HEMORRAGICAL DISEASE OF THE RABBITS.
ES2258628T3 (en) * 2001-03-08 2006-09-01 Akzo Nobel N.V. LEPORIPOX-BASED VECTOR VACCINES.
FR2946536B1 (en) 2009-06-11 2011-07-29 Agronomique Inst Nat Rech USE OF AN ATXURATED STRAIN OF MYXOMA VIRUS AS AN ONCOLYTIC
WO2017037523A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003070A1 (en) * 1993-07-22 1995-02-02 Syntro Corporation Recombinant swinepox virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003070A1 (en) * 1993-07-22 1995-02-02 Syntro Corporation Recombinant swinepox virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JACKSON, R.J. et al., "A myxoma virus intergenic transient dominant selection vector", JOURNAL OF GENERAL VIROLOGY, 1992, vol. 73, pßgs. 3241-3245. *Ver todo el documento* *
LAURENT, S. et al., "Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection", JOURNAL OF VIROLOGY, 1994, vol. 68, no. 10, pßgs. 6794-6798. *Ver todo el documento* *
OPGENORTH, A. et al., "Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11l and myxoma growth factor", JOURNAL OF VIROLOGY, 1992, vol. 66, no. 8, pßgs. 4720-4731. *Ver todo el documento* *
PERKUS, M.E. et al., "Live attenuated vaccinia and other poxviruses as delivery systems: Public health issues", ANNALS OF THE NEW YORK ACADEMY SCIENCES, 1995, vol. 754, pßgs. 222-233. *Ver todo el documento* *

Also Published As

Publication number Publication date
DE19627193B4 (en) 2007-08-30
FR2736358B1 (en) 1997-09-26
FR11C0050I2 (en) 2012-06-22
ES2113322B1 (en) 1998-12-01
FR11C0050I1 (en) 2011-12-16
FR2736358A1 (en) 1997-01-10
ITTO960578A1 (en) 1998-01-05
IT1286307B1 (en) 1998-07-08
DE19627193A1 (en) 1997-03-20
ITTO960578A0 (en) 1996-07-05

Similar Documents

Publication Publication Date Title
Lubinski et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo
Cui et al. Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency
Cairns et al. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans
Lubinski et al. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC
Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus
CN107921115B (en) Novel baculovirus vector and method of use
ATE350467T1 (en) RECOMBINANT HERPES VIRUS FROM TRUFF COCKS AND USES THEREOF
Schmaljohn et al. Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome
ES2061708T3 (en) RECOMBINANT VIRUSES OF THE GALLINA SMALLPOX, VECTORS OF EXPRESSION OF HETEROLOGICAL PROTEINS AND VACCINES FOR POULTRY DERIVED FROM THIS VIRUS.
ES2061996T3 (en) NON-ESSENTIAL REGIONS OF AVIPOXVIRUSES.
Kinchington et al. Virion association of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, requires expression of the VZV open reading frame 66 protein kinase
Geissler et al. Mapping neutralizing and non‐neutralizing epitopes on the capsid protein of feline calicivirus
WO2016196383A1 (en) Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
Wang et al. Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus
Wang et al. Generation and efficacy evaluation of a recombinant pseudorabies virus variant expressing the E2 protein of classical swine fever virus in pigs
Geltz et al. Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine
Barasa et al. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8. 1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV
Diaz et al. Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains
Liu et al. Intramuscular immunization of mice with the live-attenuated herpes simplex virus 1 vaccine strain VC2 expressing equine herpesvirus 1 (EHV-1) glycoprotein D generates anti-EHV-1 immune responses in mice
ES2113322A1 (en) Recombinant myxomatosis virus encoding non-myxomatosis antigen - for dual vaccination of rabbits and hares e.g. against myxomatosis and rabbit viral haemorrhagic disease
Ober et al. The porcine humoral immune response against pseudorabies virus specifically targets attachment sites on glycoprotein gC
Jiang et al. A mutation in the latency-related gene of bovine herpesvirus 1 inhibits protein expression from open reading frame 2 and an adjacent reading frame during productive infection
Yang et al. A domain of herpes simplex virus pUL33 required to release monomeric viral genomes from cleaved concatemeric DNA
Kawamura et al. Development of recombinant rotavirus carrying herpes simplex virus 2 glycoprotein D gene based on reverse genetics technology
Choi et al. Guinea pig cytomegalovirus protective T cell antigen GP83 is a functional pp65 homolog for innate immune evasion and pentamer-dependent virus tropism

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980416

Kind code of ref document: A1

Effective date: 19980416

FD2A Announcement of lapse in spain

Effective date: 20161026